PDCD1 and bone metastasis: Despite disease progression with local bladder recurrence and lung/bone metastasis after cisplatin-based first-line chemotherapy and docetaxel second-line monotherapy, the patient achieved sustained response after five cycles of PD-1 inhibitor sintilimab (200 mg on day 1) combined with docetaxel (120 mg on day 2, every 21 days) over 31 months, showing disappearance of nodules in the bladder, lung, and left proximal femur.